The Diphtheria vaccine stands as a pivotal achievement in preventive medicine, contributing significantly to public health worldwide. Typically administered as part of combination vaccines such as DTaP or Tdap, it effectively protects against Corynebacterium diphtheriae, the bacterium causing diphtheria. The vaccine induces an immune response, producing antibodies that neutralize the potent diphtheria toxin, preventing severe complications associated with the disease. Diphtheria, characterized by respiratory and systemic symptoms, poses a serious threat, particularly in unvaccinated or under-vaccinated populations. The vaccine's success in reducing diphtheria incidence underscores its importance in routine immunization schedules globally. Continued efforts focus on ensuring vaccine accessibility, particularly in regions with limited healthcare resources, to maintain and enhance population immunity. While the Diphtheria vaccine has been integral in controlling the disease, ongoing research explores innovative strategies for improved formulations and delivery methods, aiming for sustained global protection against this potentially deadly infection. Public awareness and vaccination campaigns remain crucial in sustaining the achievements of Diphtheria vaccination and safeguarding communities from its impact.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States